Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis
Suzanne Kafaja, Isela Valera, Anagha A. Divekar, Rajan Saggar, Fereidoun Abtin, Daniel E. Furst, Dinesh Khanna, Ram Raj Singh
Suzanne Kafaja, Isela Valera, Anagha A. Divekar, Rajan Saggar, Fereidoun Abtin, Daniel E. Furst, Dinesh Khanna, Ram Raj Singh
View: Text | PDF
Research Article Inflammation Pulmonology

pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis

  • Text
  • PDF
Abstract

Fibrosis is the end result of most inflammatory conditions, but its pathogenesis remains unclear. We demonstrate that, in animals and humans with systemic fibrosis, plasmacytoid DCs (pDCs) are unaffected or are reduced systemically (spleen/peripheral blood), but they increase in the affected organs (lungs/skin/bronchoalveolar lavage). A pivotal role of pDCs was shown by depleting them in vivo, which ameliorated skin and/or lung fibrosis, reduced immune cell infiltration in the affected organs but not in spleen, and reduced the expression of genes and proteins implicated in chemotaxis, inflammation, and fibrosis in the affected organs of animals with bleomycin-induced fibrosis. As with animal findings, the frequency of pDCs in the lungs of patients with systemic sclerosis correlated with the severity of lung disease and with the frequency of CD4+ and IL-4+ T cells in the lung. Finally, treatment with imatinib that has been reported to reduce and/or prevent deterioration of skin and lung fibrosis profoundly reduced pDCs in lungs but not in peripheral blood of patients with systemic sclerosis. These observations suggest a role for pDCs in the pathogenesis of systemic fibrosis and identify the increased trafficking of pDCs to the affected organs as a potential therapeutic target in fibrotic diseases.

Authors

Suzanne Kafaja, Isela Valera, Anagha A. Divekar, Rajan Saggar, Fereidoun Abtin, Daniel E. Furst, Dinesh Khanna, Ram Raj Singh

×

Figure 8

Detection of pDCs in the peripheral blood, BAL, and lung and skin tissues from patients with SSc and controls.

Options: View larger image (or click on image) Download as PowerPoint
Detection of pDCs in the peripheral blood, BAL, and lung and skin tissue...
(A and B) Peripheral blood mononuclear cells from 15 each of healthy controls and patients with SSc were analyzed by flow cytometry for CD11c, CD123, HLA-DR, and BDCA-2 expression. Representative dot plots show CD11c–CD123+ cells that were further analyzed for HLA-DR+BDCA-2+ cells, which are expressed as % of gated CD11c–CD123+ cells on dot plots (A). The percentage (expressed as the % of CD123+CD11c–HLA-DR+BDCA-2+ cells of total blood cells) and total number of peripheral blood pDCs were compared between healthy controls and SSc patients (B). Data are shown as individual sample values and as the mean ± SEM. **P < 0.01 and ***P < 0.001 (unpaired 2-tailed t test). (C and D) BAL cells from SSc-ILD patients before enrollment into the imatinib trial were analyzed by flow cytometry for CD11c, CD123, HLA-DR, and BDCA-2. Representative dot plots from SSc patients show CD11c–CD123+ cells that were further analyzed for HLA-DR+BDCA-2+ cells (C). BAL samples from patients who had bronchoscopy for respiratory symptoms but not found to have any significant lung disease on further evaluations were used as controls. The percentage of BAL pDCs were compared between SSc-ILD patients and controls (D). pDCs are expressed as the % of CD123+CD11c–HLA-DR+BDCA-2+ cells of total BAL cells (mean ± SEM; ***P < 0.001, unpaired t-test). (E) Paraffin-embedded sections (4 μm) of lung tissues were obtained from SSc-lung explants and control lungs (wedge resection for spontaneous pneumothorax or traumatic lung laceration or lungs collected at autopsy from cases with renal cancer or liver cirrhosis). The sections were stained with anti–BDCA-2 Ab to detect pDCs. While the control lungs had no to a few BDCA-2+ cells (left panels), all SSc lungs show BDCA-2+ cells in the interstitial tissue (middle and right panels) and bronchi (right panels). Stained sections were digitized using the Aperio scanning system. Results from individual subjects are expressed in a symbol plot as the percent IHC-stained area (mean ± SEM; *P = 0.01, unpaired 2-tailed t test). (F) Frozen sections (6 μm) of 6-mm punch skin biopsies from patients with 4 SSc and 2 healthy volunteers were stained for BDCA-2. Similar results were obtained in a separate experiment using paraffin-embedded skin sections from 4 each of SSc patients and healthy volunteers. Representative photomicrographs show no to rare BDCA-2+ cells in control skin (left panels), but abundant BDCA-2+ cells in the epidermis and dermis of 2 SSc patients: a 41-year-old man with an mRSS of 33 (middle panels) and a 21-year-old woman with an mRSS of 25 (right panels). The stained cells were manually counted, and the results from individual subjects are shown in a symbol plot as the number of pDCs per mm3 (mean ± SEM; *P = 0.01, unpaired 2-tailed t test).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts